Nucleic Acid Detection Immunoassay for Prostate-Specific Antigen Based on Immuno-PCR Methodology

McDermed, Jonathan E.; Sanders, R. D.; Fait, Stephen; Klem, Robert E.; Sarno, Mark J.; Adams, Tom; Diamandis, Eleftherios P.

doi:10.1373/clinchem.2011.170290

Cited by 29 publications

(16 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…for drug of abuse testing [4] or for clinical diagnostics, e.g. with PSA [5]. They are particularly important when the detection limits are near the clinical decision limit, as in the case of troponin [6].…”

Section: Introductionmentioning

confidence: 99%

Nonlinear Regression Improves Accuracy of Characterization of Multiplexed Mass Spectrometric Assays

Galitzine

Egertson

Abbatiello

et al. 2018

Molecular & Cellular Proteomics

View full text Add to dashboard Cite

AbbreviationsDIA data-independent acquisition LOB limit of blank LOD limit of detection LLOQ lower limit of quantitation/quantification PRM parallel reaction monitoring SRM selected reaction monitoring 2 SummaryThe need for assay characterization is ubiquitous in quantitative mass spectrometry-based proteomics. Among many assay characteristics, the limit of blank (LOB) and limit of detection (LOD) are two particularly useful figures of merit. LOB and LOD are determined by repeatedly quantifying the observed intensities of peptides in samples with known peptide concentrations, and deriving an intensity versus concentration response curve. Most commonly, a weighted linear or logistic curve is fit to the intensity-concentration response, and LOB and LOD are estimated from the fit. Here we argue that these methods inaccurately characterize assays where observed intensities level off at low concentrations, which is a common situation in multiplexed systems. This manuscript illustrates the deficiencies of these methods, and proposes an alternative approach based on non-linear regression that overcomes these inaccuracies. We evaluated the performance of the proposed method using computer simulations, and using eleven experimental datasets acquired in Data-Independent Acquisition (DIA), Parallel Reaction Monitoring (PRM), and Selected Reaction Monitoring (SRM) mode. When the intensity levels off at low concentrations, the non-linear model changes the estimates of LOB/LOD upwards, in some datasets by 20-40%. In absence of a low concentration intensity leveling off, the estimates of LOB/LOD obtained with non-linear statistical modeling were identical to those of weighted linear regression. We implemented the non-linear regression approach in the open-source R-based software MSstats, and advocate its general use for characterization of mass spectrometry-based assays.3

show abstract

Section: Introductionmentioning

confidence: 99%

Nonlinear Regression Improves Accuracy of Characterization of Multiplexed Mass Spectrometric Assays

Galitzine

Egertson

Abbatiello

et al. 2018

Molecular & Cellular Proteomics

View full text Add to dashboard Cite

show abstract

“…NADiA ProsVue -to Detect Undetectable PSA NADiA is an immunoassay derived to detect PSA nucleic acid in serum [117]. The test is based on immunopolymerase chain reaction with 2 monoclonal antibodies employed -one conjugated to DNA label and the other to paramagnetic microparticles.…”

Section: Will Urine Exosome Assays Reduce the Number Of Unnecessary Bmentioning

confidence: 99%

What Can Be Expected from Prostate Cancer Biomarkers A Clinical Perspective

Zapała

Dybowski²,

Poletajew³

et al. 2017

Urol Int

View full text Add to dashboard Cite

Along with significant advances in prostate cancer biology research, we also observe the rapid development of modern diagnostic tests. New biomarkers are derived to detect disease while it is organ-confined to stratify the risk and to aid clinical decision-making. Majority of these tools have already been validated clinically, but only a few have received premarket clearance and administration approval. Superiority of novel tests is visible not only in improved detection accuracy but predominantly in the assessment of tumour aggressiveness and selection of patients eligible for conservative management. Two factors limiting the clinical implementation of validated biomarker candidates are costs and local availability. For these reasons, currently, their true clinical role starts after routine screening with prostate-specific antigen test. With this review of prostate cancer biomarkers, we attempted to draw general conclusions on clinical perspectives of these novel tools.

show abstract

“…By calculating the amount of amplified DNA, the testing biomaterial amount can be obtained. This method has been improved by many researcher groups since its initial appearance [6][7][8][9][10]. Polycyclic aromatic hydrocarbons (PAHs) are ubiquitous environmental pollutants generated from both natural and anthropogenic processes.…”

Section: Quantitative Immuno-pcrmentioning

confidence: 99%

“…The avidin and biotinylated DNA tags are added successively following the washing step. At last, the detection signal is generated by amplification of the DNA tag application of real-time PCR in quantitative immuno-PCR significantly increased the sensitivity on substance quantitation [7,6].…”

Section: Dna Tag and Pcr For Quantitative Immuno-pcrmentioning

confidence: 99%

Novel methodologies in analysis of small molecule biomarkers and living cells

Chen

Zhu

2014

Tumor Biol.

View full text Add to dashboard Cite

Enzyme-linked immuno-sorbent assay (ELISA) is widely used for biomarker detection. A good biomarker can distinguish patients from healthy or benign diseases. However, the ELISA method is not suitable for small molecule or trace substance detection. Along with the development of new technologies, an increasing level of biomaterials, especially small molecules, will be identified as novel biomarkers. Quantitative immuno-PCR, chromatography-mass spectrometry, and nucleic acid aptamer are emerging methodologies for detection of small molecule biomarkers, even in living cells. In this review, we focus on these novel technologies and their potential for small molecule biomarkers and living cell analysis.

show abstract

Nucleic Acid Detection Immunoassay for Prostate-Specific Antigen Based on Immuno-PCR Methodology

Cited by 29 publications

References 37 publications

Nonlinear Regression Improves Accuracy of Characterization of Multiplexed Mass Spectrometric Assays

Nonlinear Regression Improves Accuracy of Characterization of Multiplexed Mass Spectrometric Assays

What Can Be Expected from Prostate Cancer Biomarkers A Clinical Perspective

Novel methodologies in analysis of small molecule biomarkers and living cells

Contact Info

Product

Resources

About